TY - JOUR
T1 - Extension of lipid-linked oligosaccharides is a high-priority aspect of the unfolded protein response
T2 - Endoplasmic reticulum stress in Type I congenital disorder of glycosylation fibroblasts
AU - Shang, Jie
AU - Körner, Christian
AU - Freeze, Hudson
AU - Lehrman, Mark A.
N1 - Funding Information:
This work was supported by NIH grant GM38545 and Welch Foundation grant I-1168 (to M.L.), NIH grants DK55615 and GM55695 (to H.F.), and Deutsche Forschungsgemeinschaft and Fonds Der Chemischen Industrie grants (to C.K.). The authors thank Drs. William Doerrler and Joel Goodman for helpful suggestions with the manuscript.
PY - 2002
Y1 - 2002
N2 - Asparagine (N)-linked glycans on endoplasmic reticulum (ER) glycoproteins have critical roles in multiple facets of protein folding and quality control. Inhibition of synthesis of lipid-linked oligosaccharides (LLOs), the precursors of N-linked glycans, causes glycoprotein misfolding. This results in ER stress and triggers the unfolded protein response (UPR), which consists of a set of adaptive events, or "aspects," including enhanced extension of LLO intermediates. Type I congenital disorders of glycosylation (CDGs) are characterized by diminished LLO synthesis and aberrant N-glycosylation. Such defects would be predicted to cause chronic ER stress with continuous UPR activation. We employed a quantitative pharmacological approach with dermal fibroblasts to show that (1) compared with three other well-known UPR aspects (transcriptional activation, inhibition of translation, and cell death), LLO extension was the most sensitive to ER stress; and (2) Type I CDG cells had a mild form of chronic ER stress in which LLO extension was continuously stress-activated, but other aspects of the UPR were unchanged. To our knowledge, Type I CDGs are the only human diseases shown to have chronic ER stress resulting from genetic defects in the ER quality control system. In conclusion, LLO extension has a high priority in the UPR of dermal fibroblasts. This suggests that cells stimulate N-glycosylation as part of a first line of defense against ER dysfunction. The broader implications of these results for the biological significance of the UPR are discussed.
AB - Asparagine (N)-linked glycans on endoplasmic reticulum (ER) glycoproteins have critical roles in multiple facets of protein folding and quality control. Inhibition of synthesis of lipid-linked oligosaccharides (LLOs), the precursors of N-linked glycans, causes glycoprotein misfolding. This results in ER stress and triggers the unfolded protein response (UPR), which consists of a set of adaptive events, or "aspects," including enhanced extension of LLO intermediates. Type I congenital disorders of glycosylation (CDGs) are characterized by diminished LLO synthesis and aberrant N-glycosylation. Such defects would be predicted to cause chronic ER stress with continuous UPR activation. We employed a quantitative pharmacological approach with dermal fibroblasts to show that (1) compared with three other well-known UPR aspects (transcriptional activation, inhibition of translation, and cell death), LLO extension was the most sensitive to ER stress; and (2) Type I CDG cells had a mild form of chronic ER stress in which LLO extension was continuously stress-activated, but other aspects of the UPR were unchanged. To our knowledge, Type I CDGs are the only human diseases shown to have chronic ER stress resulting from genetic defects in the ER quality control system. In conclusion, LLO extension has a high priority in the UPR of dermal fibroblasts. This suggests that cells stimulate N-glycosylation as part of a first line of defense against ER dysfunction. The broader implications of these results for the biological significance of the UPR are discussed.
KW - Congenital disorder of glycosylation
KW - Endoplasmic reticulum stress
KW - Glycosylation
KW - Lipid-linked oligosaccharide
KW - Unfolded protein response
UR - http://www.scopus.com/inward/record.url?scp=0036020877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036020877&partnerID=8YFLogxK
U2 - 10.1093/glycob/12.5.307
DO - 10.1093/glycob/12.5.307
M3 - Article
C2 - 12070073
AN - SCOPUS:0036020877
SN - 0959-6658
VL - 12
SP - 307
EP - 317
JO - Glycobiology
JF - Glycobiology
IS - 5
ER -